Novel synthetic opioids (NSOs), including both fentanyl and non-fentanyl analogs that act as
μ-opioid receptor (MOR) agonists, are associated with serious intoxication and fatal�…

Opioid addiction is characterized by adaptations in the mesolimbic dopamine system that
occur during chronic opioid use. Alterations in dopaminergic transmission contribute to�…

Issues Opioid overdose kills over 100,000 people each year globally. Mobile health
(mHealth) technologies and devices, including wearables, with the capacity to prevent�…

Background: Autistic transgender people face unique risks in society, including inequities in
accessing needed care and related mental health disparities. Given the need for specific�…

Opioid agonist treatment (OAT) is the primary intervention for opioid use disorder (OUD) in
Canada and the USA. Yet, a number of barriers contribute to sub-optimal treatment uptake�…

Alexithymia is related to a higher severity of substance use disorders (SUD); however, few
longitudinal studies have been performed on how alexithymia impacts treatment outcomes�…

Background: Recent studies suggest that the funding breakdown of autism research in the
United States may not align with stakeholder priorities. Furthermore, the majority of�…

Abstract Objective: Situated in Children's National Hospital (CNH)'s Neuropsychology
Division, the Gender and Autism Program (GAP) is the first clinical service dedicated to the�…

Abstract Background and Objectives Alcohol use disorder (AUD) is a significant public
health concern, with underutilized effective treatments, particularly in special populations�…

Buprenorphine and methadone are the two main opioid agonist treatments approved for
opioid use disorder. Buprenorphine is a partial agonist of the mu opioid receptors, which has�…